Summary of observed on schedule, early termination, and imputed MRI scores.
| Placebo | Baricitinib | |||||
|---|---|---|---|---|---|---|
| 1 mg | 2 mg | 4 mg | 8 mg | |||
| Joint damage outcomes (bone erosion, cartilage loss) | ||||||
| Baseline | Observed | 48 | 27 | 29 | 26 | 24 |
| Week 12 | Total analyzed | 39 | 25 | 29 | 25 | 24 |
| Observed on schedule | 38 | 25 | 28 | 24 | 24 | |
| Observed early termination | 1 | 0 | 1 | 1 | 0 | |
| Imputed (LE) | 1 | 0 | 1 | 1 | 0 | |
| Week 24 | Total analyzed | 39 | 25 | 29 | 25 | 24 |
| Observed on schedule | 0 | 0 | 27 | 19 | 23 | |
| Observed early termination | 39 | 25 | 2 | 6 | 1 | |
| Imputed (LE) | 39 | 25 | 2 | 6 | 1 | |
| Patients with inflammation outcomes (synovitis, osteitis) | ||||||
| Baseline | Observed | 48 | 27 | 29 | 26 | 24 |
| Week 12 | Total analyzed | 48 | 27 | 29 | 26 | 24 |
| Observed on schedule | 38 | 25 | 28 | 24 | 24 | |
| Observed early termination | 1 | 0 | 1 | 1 | 0 | |
| Imputed (LOCF) | 10 | 2 | 1 | 2 | 0 | |
| Week 24 | Total analyzed | 48 | 27 | 29 | 26 | 24 |
| Observed on schedule | 0 | 0 | 27 | 19 | 23 | |
| Observed early termination | 39 | 25 | 2 | 6 | 1 | |
| Imputed (LOCF) | 48 | 27 | 2 | 7 | 1 | |
MRI: magnetic resonance imaging; LE: linear extrapolation; LOCF: last observation carried forward.